OncoMatch/Clinical Trials/NCT06444009
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Is NCT06444009 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ivonescimab combined with TP and Cadonilimab combined with TP for head and neck squamous cell carcinoma.
Treatment: Ivonescimab combined with TP · Cadonilimab combined with TP · Penpulimab combined with TP — A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection. This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any anti-tumor treatment
Lab requirements
Blood counts
total white blood cell count ≥ 3.0×10^9/l, absolute lymphocyte count ≥ 0.8×10^9/l, absolute neutrophil count ≥ 1.5×10^9/l, platelets ≥ 100×10^9/l, hemoglobin ≥ 90g/l
Kidney function
serum creatinine ≤ 1.5 times uln or calculated creatinine clearance ≥ 60 ml/min (cockcroft-gault formula), urine protein <2+ on dipstick or <1g in a 24-hour urine collection
Liver function
bilirubin level ≤ 2 times the upper limit of normal (uln); aspartate aminotransferase (ast) and alanine aminotransferase (alt) levels ≤ 2.5 times uln
Cardiac function
normal or clinically insignificant abnormalities on electrocardiogram (ecg), echocardiogram showing a left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify